Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
暂无分享,去创建一个
S Hulley | E. Vittinghoff | C. Furberg | D. Herrington | S. Hulley | D. Grady | T. Bush | B. Riggs | E Vittinghoff | C Furberg | D Grady | T Bush | D Herrington | B Riggs
[1] R. Califf,et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.
[2] S B Hulley,et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. , 1998, Controlled clinical trials.
[3] R. Blumenthal,et al. Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III) , 1998, American heart journal.
[4] R. Rosenson,et al. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.
[5] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[6] JoAnn E. Manson,et al. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.
[7] E. Barrett-Connor,et al. Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.
[8] Julian Peto,et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.
[9] S. Sidney,et al. Myocardial Infarction and the Use of Estrogen and Estrogen-Progestogen in Postmenopausal Women , 1997, Annals of Internal Medicine.
[10] C. Furberg,et al. Venous thromboembolic events associated with hormone replacement therapy. , 1997, JAMA.
[11] K. McPherson,et al. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials , 1997, BMJ.
[12] David M. Herrington,et al. Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women With Heart Disease: The Heart and Estrogen/Progestin Replacement Study (HERS) , 1997 .
[13] K. Ramanathan,et al. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. , 1997, American Journal of Cardiology.
[14] J. Castellsagué,et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study , 1997, BMJ.
[15] A. LaCroix,et al. Estrogen replacement therapy and prognosis after first myocardial infarction. , 1997, American journal of epidemiology.
[16] M. Adams,et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[17] J. O’Keefe,et al. Estrogen replacement therapy after coronary angioplasty in women. , 1997, Journal of the American College of Cardiology.
[18] J. Rossouw. Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon. , 1996, Circulation.
[19] R. Califf,et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. , 1996, Journal of the American College of Cardiology.
[20] J. Carson,et al. Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.
[21] J. Manson,et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women , 1996, The Lancet.
[22] K. Newton,et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens , 1996, The Lancet.
[23] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[24] A. Keech,et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post‐menopausal women , 1996, Clinical endocrinology.
[25] J. Manson,et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.
[26] R. Cannon,et al. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. , 1996, Circulation.
[27] K. Matthews,et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? , 1996, American journal of epidemiology.
[28] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[29] M. Crawford,et al. Estrogen and cardiovascular function after menopause. , 1995, Journal of the American College of Cardiology.
[30] P. M. Sarrel. How Progestins Compromise the Cardioprotective Effects of Estrogens , 1995 .
[31] T. Clarkson,et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. , 1994, Journal of the American College of Cardiology.
[32] David C. Atkins,et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. , 1994, Archives of internal medicine.
[33] D. Petitti. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? , 1994, Annals of epidemiology.
[34] R. Mann,et al. A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. , 1994, Journal of clinical epidemiology.
[35] S. Shapiro,et al. A case-control study of myocardial infarction in relation to use of estrogen supplements. , 1993, American journal of epidemiology.
[36] Caroline S. Fox,et al. Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.
[37] E. Eaker,et al. The risk of acute myocardial infarction after oestrogen and oestrogen‐progestogen replacement , 1992, British journal of obstetrics and gynaecology.
[38] P M Rautaharju,et al. NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. , 1992, Journal of electrocardiology.
[39] E. Barrett-Connor. Postmenopausal estrogen and prevention bias. , 1991, Annals of internal medicine.
[40] B. Henderson,et al. Decreased Mortality in Users of Estrogen Replacement Therapy , 1991, Archives of internal medicine.
[41] G. Colditz,et al. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .
[42] P. Allhoff,et al. Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle Aged Men with Dyslipidemia , 1991 .
[43] G. Everson,et al. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. , 1991, The Journal of clinical investigation.
[44] D. Mirvis,et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. , 1990, Archives of internal medicine.
[45] J. Cauley,et al. Prevalence and determinants of estrogen replacement therapy in elderly women , 1990, American journal of obstetrics and gynecology.
[46] S. Manuck,et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. , 1990, Arteriosclerosis.
[47] J P Matts,et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.
[48] T. Meade,et al. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. , 1989, Journal of epidemiology and community health.
[49] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[50] E. Barrett-Connor,et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. , 1987, Circulation.
[51] E. Barrett-Connor,et al. Noncontraceptive estrogen use and cardiovascular disease. , 1985, Epidemiologic reviews.
[52] Max Halperin,et al. More flexible sequential and non-sequential designs in long-term clinical trial , 1984 .
[53] The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.